Press Release November 15, 2019

Promedior Enters Into Definitive Merger Agreement to be Acquired by Roche in Transaction Valued Up to $1.39 Billion

The Life Sciences team advised Promedior, Inc. on its definitive merger agreement for Roche (SIX: RO, ROG;OTCQX: RHHBY) to acquire Promedior. Roche will make an upfront cash payment of $390 million, plus additional contingent payments of up to $1 billion based on the achievement of certain predetermined development, regulatory and commercial milestones.

Promedior, a privately held clinical-stage biotechnology company based in Lexington, Massachusetts, has successfully advanced PRM-151 in human clinical trials and received Breakthrough Therapy Designation from the FDA earlier this year for idiopathic pulmonary fibrosis (IPF). With this acquisition, global pharmaceuticals company Roche will obtain full rights to Promedior's entire portfolio of molecules for serious fibrotic diseases, notably PRM-151.

The Goodwin team was led by Jason Breen and Kingsley Taft, and included Amoli Pandya, Sean Montgomery, Kim Larie, Joshua Tarr and Tracey Parker (corporate), Erini Svokos and Yasee Zahedi (licensing), Dan Karelitz and Kyle Pine (tax), Julie Tibbets and Allyson Maur (FDA), and James Mattus, Morgan Frisoli, Jennifer Fagan, Jennifer Fay, Tim Holahan and Lee Douthitt (employment).

For more details, read the press release and articles in Reuters, Endpoints and The Deal.